RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC)
Fizazi, K., Shore, N. D., Tammela, T., Kuss, I., Le Berre, M-A., Mohamed, A. F., Odom, D., Bartsch, J., Snapir, A., Sarapohja, T., & Smith, M. R. (2019). Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology, 37(15). https://doi.org/10.1200/JCO.2019.37.15_suppl.5000
